Dr Dimopolous presents results at EHA 23 from the iNNOVATE trial of rituximab with or without oral BTK-inhibitor ibrutinib to Waldenströms Macroglobulinemia.

He outlines the study design, with patients randomised 1:1 to receive ibrutinib or placebo orally until disease progression, and the improved progression-free survival of those patients receiving the added therapy.

No unexpected toxicities were reported in the trial, and response rates exceed those of patients receiving rituximab based therapy alone.

For more on this trial, watch presentation of the data at a press session here.